An infusion is the introduction of a medication, or fluid, directly into a vein by means of gravity flow.

Biliscopin® Infusion, an iodinated contrast medium for intravenous cholecystography is secreted actively by the hepatocytes. The biliary excretion rate of a biliary contrast medium is determined by the binding to plasma proteins and liver receptor proteins, and by its transport maximum for the liver. Because of its high hepatocellular transport rate, Biliscopin® Infusion leads rapidly to high grade contrast density in the intra-hepatic and extra-hepatic biliary ducts as well as in the gallbladder.
Computed tomography with biliary contrast agents provides maximum quality preoperative imaging of the biliary tract.

The Germany-based pharmaceutical company is the result of the take-over of Schering AG by Bayer AG in 2006. The Bayer Schering Pharma AG is part of the Bayer HealthCare AG, which represents the pharmaceutical part of the Bayer Group. Activities of the Bayer Schering Pharma AG are Diagnostic Imaging, Hematology & Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. The diagnostic imaging part's contrast agents for MRI, x-ray and CT are 'world-market leaders'.
See also Bayer HealthCare Pharmaceuticals.

The molecular structure of some iodinated contrast agents makes them suitable for the computer-tomographic examination of the biliary tract. Organic iodine compounds increase the attenuation of x-rays and the contrast between body tissues containing iodine and those tissues that do not contain iodine. The degree of opacification is directly proportional to the concentration and volume of the iodinated contrast agent (the total amount of iodine).
Biliary contrast agents can be taken orally, for example calcium iopodate, or intravenous meglumine iotroxate. The contrast media are excreted by the liver and concentrate in the gallbladder after passing the intrahepatic biliary tree and cystic duct.
Oral biliary contrast agents usually opacify the gallbladder after a few hours. If the gallbladder is removed, an intravenous cholegraphic agent is required and gallbladder CT can start 60 minutes after the beginning of contrast medium infusion.
The main limitation of the use of biliary contrast agents is the high rate of allergic reactions and of renal or hepatic toxicity. Caused by the potential for systemic toxicity with intravenous cholangiography, ultrasonography should be the preferred method for evaluation of the gallbladder and the bile ducts.

Hypaque Meglumine is an ionic contrast agent. Hypaque Meglumine 60 percent (w/v) is an aqueous solution containing 60 g of the meglumine salt of diatrizoic acid per 100 mL of solution.
The degree of contrast enhancement at computed tomography is directly related to the amount of iodine administered. In adults the amount of iodine usually required for contrast enhancement ranges from 28 to 42 g.
Hypaque Meglumine is also available in concentrations of 18% and 30%.